Skip to main content
SillaJen, Inc. logo

SillaJen, Inc. — Investor Relations & Filings

Ticker · 215600 ISIN · KR7215600008 KO Professional, scientific and technical activities
Open in API
Filings indexed 402 across all filing types
Latest filing 2025-09-09 Regulatory Filings
Country KR South Korea
Listing KO 215600

About SillaJen, Inc.

https://www.sillajen.com/

SillaJen, Inc. is a biotechnology company focused on the research and development of oncolytic immunotherapeutics for cancer treatment. The company engineers genetically modified viruses designed to selectively target and destroy cancer cells while stimulating a systemic anti-tumor immune response. Its lead product candidate is Pexa-Vec (JX-594), an oncolytic vaccinia virus developed for the treatment of various solid tumors. SillaJen's core activity involves advancing its pipeline of novel cancer-fighting viral therapies through clinical development.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획변경승인) (진행성 고형암 또는 재발성/불응성 급성 골수성 백혈병 환자를 대상으로 BAL0891의 단일요법 및 항암화학요법 및 티스렐리주맙과의 병용요법에 대한 식품의약품안전처 제1상 임상시험 계획 변경 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Major Management Matter' (투자판단 관련 주요경영사항) disclosure. It details the approval of a clinical trial plan (IND) amendment by the Ministry of Food and Drug Safety (MFDS). This type of disclosure is a standard regulatory announcement for publicly traded companies in Korea regarding material business developments. Since it does not fit into specific categories like financial reports, proxy statements, or dividend notices, it falls under the 'Regulatory Filings' (RNS) category.
2025-09-09 Korean
[기재정정]사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a 'Correction Report' (정정신고) for an Annual Report (사업보고서) filed by SillaJen, Inc. It explicitly states that it is a correction to the previously submitted Annual Report (10-K equivalent in the Korean market) due to regulatory requirements from the Financial Supervisory Service. Since it contains substantive financial and corporate governance data and is a formal amendment to the annual filing, it is classified as an Annual Report (10-K). FY 2024
2025-08-14 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for SillaJen, Inc., covering the period from January 1, 2025, to June 30, 2025. It contains comprehensive financial and operational information, including company overview, history, capital changes, and business activities. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial and operational data for a period shorter than a full fiscal year. H1 2025
2025-08-14 Korean
불성실공시법인지정 (공시변경)
Regulatory Filings Classification · 100% confidence The document is a regulatory announcement from the Korea Exchange (KOSDAQ) regarding the designation of SillaJen as an 'unfaithful disclosure corporation' due to a change in disclosure. It details the violation, the penalty (fine), and the regulatory basis. Since this is a specific regulatory notice regarding compliance and disclosure violations that does not fit into financial reporting or corporate action categories, it is classified as a Regulatory Filing (RNS).
2025-08-05 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (진행성 고형암 또는 재발성/불응성 급성 골수성 백혈병 환자를 대상으로 BAL0891의 단일요법 및 항암화학요법 및 티스렐리주맙과의 병용요법에 대한 미국 FDA 제1상 임상시험 계획 변경 승인 신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically an application for a change in clinical trial plans (IND) for the drug BAL0891. This is a standard corporate disclosure for pharmaceutical companies in Korea. Since it does not fit into specific categories like M&A, dividends, or financial reports, and is a formal regulatory announcement, it is classified as a Regulatory Filing (RNS).
2025-07-15 Korean
불성실공시법인지정예고 (공시변경)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory notice from the KOSDAQ market regarding the 'Notice of Designation as an Unfaithful Disclosure Corporation' (불성실공시법인지정예고). It details a specific regulatory action, the grounds for the designation, and potential consequences such as trading suspension or eligibility review. Since this is a specific regulatory notification regarding compliance and disclosure status that does not fit into financial reporting or corporate action categories, it is classified as a Regulatory Filing (RNS).
2025-07-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.